Oncology
News
Novel Anticoagulant Prevents VTEs During Chemotherapy
Major Finding: The rate of VTE events was 1.2% in patients given prophylactic semuloparin vs. 3.4% in a control group treated with placebo (HR, 0....
News
Rituximab Maintenance Called "New Standard" for Mantle Cell Lymphoma
Major Finding: After induction therapy, rituximab-treated patients experienced a median remission of 77 months, compared with 24 months in...
Conference Coverage
Rich Patients With Poor Prognosis Cancers Get More Treatment
Major Finding: For the lowest socioeconomic group of patients with lung cancer, radiation therapy was given to 44%, surgery to 13%, and...
News
Denosumab Not Cost Effective in Solid Tumor Bone Metastases
Major Finding: Use of denosumab results in an incremental cost per QALY gained of $644,000 in breast cancer and $1.25 million in prostate cancer....
News
FDA Approves Cancer Drugs Faster Than European Agency
Major Finding: The U.S. Food and Drug Administration approves new cancer therapies in a median of 182 days, compared with 350 days for the...
News
Chemo Length May Not Affect Survival in Some B-cell Lymphomas
Major Finding: The 2-year overall survival rates were 81% in the R-CHOP-21 arm, and 83% in the R-CHOP-14 arm (log rank P = .70).
News
Iniparib Loses Blockbuster Image in Triple-Negative Breast Cancer
Major Finding: The addition of iniparib to chemotherapy resulted in insignificant improvements in median progression-free survival (4.1 months vs...
Conference Coverage
Transplant in First Remission Holds Off Progression in Non-Hodgkin's Lymphoma
Major Finding: Estimated 2-year progression-free survival was 69% among patients randomized to CHOP chemotherapy with/without rituximab plus...
News
Smoking Bans, Taxes Could Save Nearly $2 Billion in Health Costs
Conference Coverage
European Trial Upholds Use of Erlotinib in EGFR-Mutant Lung Cancer
Major Finding: Erlotinib resulted in a significant 63% reduction in the risk of progression, compared with standard chemotherapy (HR 0.37).Data...